Drug combination for advanced tumors with CLDN18.2 protein
Part of Cancer clinical trials.
This clinical trial tests a combination of two new drugs, FG-M108 and FG-B901, for people with advanced solid tumors that have a specific protein marker (CLDN18.2). The goal is to see if the combination is safe and effective when standard treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor cancer (any type) that is advanced or has spread, and standard treatments have stopped working or aren't available.
- Your tumor cells test positive for a protein called CLDN18.2 (at least 10% of cells show it).
- You are between 18 and 75 years old.
- You are fully active or able to do light work (ECOG 0 or 1).
- Your doctor expects you to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (FG-M108) combined with standard chemotherapy, compared to chemotherapy alone, for people with advanced pancreatic cancer that has not been treated before. It is for those whose tumors have a specific protein (Claudin18.2) that the drug is designed to attack.
This trial tests a combination of two new study drugs (QLS31905 and QL1706) plus chemotherapy against advanced solid tumors that have a specific protein called Claudin18.2. It's for people who have not had any prior treatment for their advanced cancer.
This trial tests a new drug called LCB02A, which targets a protein called Claudin 18.2 found on some cancer cells. It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests a new drug called FG-B901, either by itself or combined with chemotherapy, in people with advanced cancer that has spread or didn't respond to standard treatments. The goal is to see if it can shrink tumors and help patients live longer.
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
This trial tests a new drug, SIBP-A18, for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers that have a protein called CLDN18.2.
Hear when a new Claudin 18.2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.